Gestational diabetes & diabetes in pregnancy
Continuous Glucose Monitoring Metrics for Predicting Adverse Neonatal Outcomes in Individuals Undergoing Gestational Diabetes Screening
Authors' conclusion
Continuous glucose monitoring metrics reflecting sustained or high-level hyperglycemia, rather than GV-focused metrics, more strongly predicted adverse neonatal outcomes.
Study context
- Population
- Pregnant individuals undergoing gestational diabetes screening, wearing continuous glucose monitoring (CGM) for 10 days after a 1-hour 50 g glucose challenge test
- Participants
- 84 individuals
- Comparison
- CGM metrics vs original ≥10% time above 140 mg/dL measure for predicting adverse neonatal outcomes
- Outcome
- Composite neonatal outcome:
- Large-for-gestational-age birth
- Need for IV glucose treatment
- Shoulder dystocia
Methodological detailsgeneralized estimating equation logistic regression
- Generalized estimating equation logistic regression
Performance
As reported in the abstract
Discrimination (AUROC) of CGM metrics for composite adverse neonatal outcome
- AUROC, original ≥10% time-above-range measure
- 0.643
- AUROC, SD
- 0.656
- AUROC, mean amplitude of glycemic excursions (MAGE)
- 0.665
- AUROC, mean glucose
- 0.676
- AUROC, glucose management indicator (GMI)
- 0.676
- AUROC, maximum glucose
- 0.683
- AUROC, %Time >120 mg/dL
- 0.683
- AUROC, AUC-CGM
- 0.692
- AUROC, high blood glucose index (HBGI)
- 0.701
- AUROC, %Time >140 mg/dL
- 0.703
- Mean glucose, SD, maximum glucose, %Time >140 mg/dL, %Time >120 mg/dL, GMI, mean of daily differences (MODD), MAGE, AUC-CGM and HBGI significantly associated with adverse neonatal outcomes
- P < .05
Original publication
Continuous Glucose Monitoring Metrics for Predicting Adverse Neonatal Outcomes in Individuals Undergoing Gestational Diabetes Screening. J Diabetes Sci Technol. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →